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GenomicsThe licensed smallpox vaccine, comprised of infectious vaccinia, is no longer popular as it is associated with a
variety of adverse events. Safer vaccines have been explored such as further attenuated viruses and
component designs. However, these alternatives typically provide compromised breadth and strength of
protection. We conducted a genome-level screening of cowpox, the ancestral poxvirus, in the broadly
immune-presenting C57BL/6 mouse as an approach to discovering novel components with protective
capacities. Cowpox coding sequences were synthetically built and directly assayed by genetic immunization
for open-reading frames that protect against lethal pulmonary infection. Membrane and non-membrane
antigens were identiﬁed that partially protect C57BL/6 mice against cowpox and vaccinia challenges without
adjuvant or regimen optimization, whereas the 4-pox vaccine did not. New vaccines might be developed
from productive combinations of these new and existing antigens to confer potent, broadly efﬁcacious
protection and be contraindicated for none.
© 2009 Elsevier Inc. All rights reserved.Introduction
Despite having a vaccine in hand that eliminated natural smallpox
infections, new vaccines are needed to protect against the threat of
deliberately released variola in addition to other endemic and
emerging poxviruses. Poxviridae contains viruses with linear gen-
omes of double-stranded DNA that replicate in the host cytoplasm and
can encode more than 200 proteins, making them one of the largest
among all viruses (Henderson, 1999). The orthopoxviruses produce
several structural forms, including two infectious particles that have
distinct membrane surfaces and roles in the viral life cycle. The
intracellular mature virion (IMV) is important for host to host trans-
mission (Lustig et al., 2005; Vanderplasschen et al., 1998), while the
extracellular enveloped virion (EEV) contributes to efﬁcient dissem-
ination within a host (Lustig et al., 2005; Vanderplasschen et al.,
1998). The orthopox genus contains variola, cowpox, vaccinia,
ectromelia (mousepox), monkeypox, and several other closely related
viral species that show extensive serological cross-reactivity and
vaccine cross-protection (Edghill-Smith et al., 2005; Heraud et al.,
2006; Parrino and Graham, 2006). However, variola (VARV) survivorsona State University, P.O. Box
1 480/727 0756.
ll rights reserved.are protected from smallpox disease for life whereas people
immunized with live VACV display reduced immunity within 10 to
20 years (Jacobs, 2002; Viner and Isaacs, 2005). Cowpox (CPV) appears
to be the ancestral poxvirus (Dasgupta et al., 2007; Shchelkunov et al.,
1998), maintained for thousands of years in its natural rodent host,
though cattle infections are also common (Wang et al., 2008) and
human infections are considered an emerging hazard (Vorou et al.,
2008). VACV has no known natural host nor clear origin; it has been
suggested to be a divergent CPV or VARV species that emerged during
early variolation practices (Buller and Palumbo, 1991).
Live CPV was used by Jenner in his original demonstration of
protective immunity against smallpox. CPV was gradually replaced
with VACV because of this newer virus' lower virulence (Buller and
Palumbo, 1991), although both viruses can cause disease in humans
(Moore et al., 2006). A process for large-scale production of
lyophilized VACV from infected calf lymph was developed in the
1940s (Moss, 1991). This product ironically made research toward a
better smallpox vaccine superﬂuous for decades. However, our
current society expects greater vaccine product performance, unifor-
mity, and safety. The US DryVax product was not produced under
good manufacturing practice (GMP) protocols, and its efﬁcacy varied
among batches (Slifka, 2005). Life-threatening complications (Hen-
derson, 1999) and cardiac-related adverse events (Karron et al., 2005)
remain concerns. Estimates indicate that half of the US population
would be excluded from receiving a vaccination due to histories of
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for infants, elderly, pregnant women, and our increasing immuno-
compromised sector (LeDuc and Becher, 1999).
To address these difﬁculties, newer generation vaccines have been
developed from VACV grown in cell culture (Weltzin et al., 2003). This
improved batch consistency but showed reactogenicity similar to
that of the original product (Ward et al., 2005). Attenuated VACVs
have been widely investigated, such as the LC16m8 strain, Modiﬁed
Vaccinia Ankara (MVA), and a number of other more recent ones
(Vollmar et al., 2006). The potency and safety of these further
modiﬁed live virus inocula are under continued study.
Poxviruses are notable for their abilities to interfere with or
circumvent many critical processes of the host innate and adaptive
immune responses upon infection (Dasgupta et al., 2007; Dunlop et al.,
2003; Thornburg et al., 2007). Since these properties are counter-
productive for vaccine inocula, component designs may hold advan-
tage. Unfortunately optimal subunit selection is stymied by our
incomplete knowledge of the immune mechanisms needed to protect
against these complex viruses and the diversity of systems used to
model human variola disease. Researchers are currently using the
VACV, ectromelia (ECTV), and CPV viruses in mice in addition to the
MPV in primates to evaluate vaccine designs. Immune studies have
indicated that both antibody and cellular responses are involved
(Cornberg et al., 2007), but relatively few antigens have been tested.
USAMRIID scientists assembled four VACV genes (A27L, A33R, B5R,
and L1R), encoding two major IMV and two major EEV surface pro-
teins, and showed that biolistic co-immunization protects BALB/c
mice against an intraparenterally (i.p.) delivered VACV challenge
(Hooper et al., 2003) or CPV challenge (Pickup, 2007). Primates are
also protected against an intravenous MPV challenge (Hooper et al.,
2004). This tetravalent inoculum has been referred to as “4-pox”.
Subsets of these four antigens delivered as gene, replicon or protein,
have shown various levels of protection against VACV challenges in
mice (Golden and Hooper, 2008; Hooper et al., 2000; Pulford et al.,
2004; Sakhatskyy et al., 2008; Thornburg et al., 2007; Xiao et al., 2007).
Other mouse protection studies showed immunization with H3L or a
codon-optimized D8L provides some protection against VACV chal-
lenge (Davies et al., 2005; Sakhatskyy et al., 2006), and an antibody
against A28L is passively protective (Nelson et al., 2008). Using the
ECTV murine model, a peptide from B8R and protein B19R VACV
homologues was shown to confer partial protection (Tscharke et al.,
2005; Xu et al., 2008). Finally, VARV antigens A30, B7, and F8 have
shown to be protective against VACV challenge in mice (Sakhatskyy et
al., 2008). While it is not clear whether or not these particular surface
proteins or their VARV homologues would be protective against
exposure to VARV, these studies demonstrate that isolated viral com-
ponents can protect against orthopoxvirus infections. They also
indicate that biolistic genetic immunization is at least one effective
modality of vaccine delivery. Unfortunately, none of the inocula were
as effective as live VACV and all required relatively large doses and
multiple immunizations. Additional candidates, with perhaps unique
immune capacities, may be needed to successfully develop a modern
vaccine.
We report here a comprehensive screen of the cowpox virus for
protective components encoded by its genome, using expression
library immunization (ELI) (Barry et al., 2004) and a pulmonary
challenge assay in C57BL/6 mice. In this approach, the full protein
coding capacity of a pathogen is introduced into host animals as
matrix-organized pools of genes or subgenes by genetic immuniza-
tion (Tang et al., 1992). Animals are exposed to pathogen and disease
is monitored as a readout of inoculum utility. Optimally, all open-
reading frames (ORFs) should be expressed at similar levels to avoid
bias in the screen. We chose to synthetically build the ORFs as codon-
optimized versions. This enabled us to uniformly increase expression
and normalize antigen dose. Even though nearly all vaccine studies to
date have been conducted with the BALB/c mouse, we selectedC57BL/6 mice as the host strain for our vaccine assay because the
BALB/c does not produce a broad proﬁle of cellular immune res-
ponses against viral infection (Dieli et al., 1988; Janeway et al., 2005)
whereas the C57BL/6 does (Moutaftsi et al., 2006); furthermore, any
widely useful candidate would need to be effective in more than one
genetic background. Research has indicated that delivery routes can
inﬂuence which components of 4-pox are needed for protection
(Kaufman et al., 2008). Since we are targeting candidates for pro-
tection against aerosol exposure to virus, a pulmonary challenge
delivery route was chosen for our antigen screen. In particular, viral
infections were administered intratracheally (i.t.), as this is most
reliable method for delivering viral particles to the lower respiratory
tract (MacNeill et al, 2009).
Nine new protective antigen candidates are presented, including
six that are either non-membrane or hypothetical proteins, and
unlikely to have been rationally selected. This contrasts with pre-
viously tested set of antigens, which have all been surface proteins.
We propose that these new functionally identiﬁed antigens, in com-
bination with existing ones, constitute a uniquely diverse panel of
molecular candidates fromwhich a broadly efﬁcacious subunit vaccine
against smallpox and other emergent poxvirus diseases might be
developed.
Results
Premise for new antigen discovery
The most characterized VACV genes identiﬁed as orthopoxvirus
vaccine candidates are the constituents of the 4-pox gene inoculum. A
desirable orthopox vaccine would be cross-protective against more
than one these related viral species; indeed VACV 4-pox has been
shown to cross-protect against CPV infections in BALB/c mice and
MPV in primates. We reasoned that a successful vaccine will also need
to protect a diverse host species population. To address this question,
we tested the performance of the 4-pox inoculum in C57BL/6 mice
relative to its effectiveness in the well-studied BALB/c strain.
Evaluation of the 4-pox gene constructs as a vaccine candidate
The VACV genes encoding A27L, A33R, B5R, and L1R and also the
corresponding CPV homologues were extracted from GenBank and
redesigned as codon-optimized versions using our GeneBuilder
program. These were built as described in Materials and methods
and cloned into plasmid vector pCMViLS, which expresses inserted
sequences with the secretory leader peptide (LS) from human alpha-1
antitrypsin. The four plasmids were co-administered biolistically into
both sides of both ears (4 μg total DNA per mouse) of groups of 10
BALB/c and C57BL/6 mice. Positive control groups were administered
a VACV or CPV live vaccine and negative controls were naïve age-
matched. Boosts were administered at week 2 post-prime and animals
were homologously challenged i.t. with a lethal dose of VACV or CPV
at week 6. The survival results plotted in Fig. 1A show that the live
vaccines were fully protective and the 4-pox inocula partially
protected BALB/c mice from VACV or CPV exposure. These results
are consistent with those published by others (Hooper et al., 2003). In
the C57BL/6 model, the live vaccines were also fully protective;
however, the same 4-pox inocula did not protect these mice (Fig. 1B).
Experimental design and pilot studies
The ELI screen was designed so as to assay the vaccine potential of
each CPV gene or subgene three times, within different antigenic
contexts. This was done by applying three different strategies for
distributing the library of ORFs into 25 sub-library pools. Every ORF
resided once in each library set (named X, Y, and Z) and thereby was a
component of three of the total collection of 75 uniquely comprised
Fig. 1. Comparison of protection conferred by 4-pox gene vaccine in two strains of mice.
Animals (10 mice per group) were biolistically immunized with a pool of VACV A27L,
A33R, B5R, and L1R or the CPV homologues of these genes and boosted 2 weeks later. A
lethal dose of virus (VACV strain Western Reserve, or CPV Brighten Red) was
administered 6 weeks post-prime by i.t. route, and survival was monitored for 21 days.
Kaplan–Meir plots were drawn and relative to live virus vaccinated and naïve mice. (A)
The BALB/c mouse strain was used as host. (B) The C57BL/6 mouse strain was used as
host.
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three-dimensional array of ORFs within a cube. Each ORF's position
can be deﬁned using an X, Y, and Z planar coordinate and therefore
matrix-based analyses can pinpoint individual ORFs that are in
common within any X, Y, and Z pool. These organized overlaps
enable a single animal experiment to be used to infer which ORFs are
responsible for animal protection and provide each ORF with a
calculated rank relative to its apparent ability to induce protective
immunity. Several pilot studies were conducted to demonstrate the
feasibility of performing this multiplexed protection experiment.
Validating immunogenicity of synthetic gene pools
Before constructing the library, we built a set of test genes
encoding well-known antigens. This would enable us to conﬁrm that
pools of synthetic gene expression constructs work in vivo to
stimulate speciﬁc immune responses. In addition to using the CPV
homologues of vaccinia virus genes A27L, A33R, B5R, and L1R, we
included the HSV-1 glycoprotein D (gD) gene, the Yersinia pestis V
antigen, and the domain 4 of the anthrax protective antigen (PA4)(Flick-Smith et al., 2002b). The GenBank sequences were extracted,
recoded, and built cloned into the plasmid vector pCMViLS. The same
cloning strategy was used as planned for library construction. The
seven plasmids were co-administered biolistically (1 μg total DNA per
shot) into both ears of a group of 10 C57BL/6 mice. Boosts were
administered at week 4 post-immunization and blood was drawn
2 weeks after the boost from both immunized and naïve age-matched
control animals. Pooled sera were tested for speciﬁc reactivity against
each of the antigens by ELISA. The reciprocal dilution curves in Fig. 2A
show that antigen-speciﬁc antibody responses were generated by
four of the seven constructs in the immunization inoculum. The
immune sera reacted with gD, PA4, A27L, and A33R but not V antigen,
B5R, or L1R. As gene vaccines, B5R, L1R, and V antigen have been
found to be weaker B cell immunogens relative to the other antigens
in the group (Flick-Smith et al., 2002a); therefore, the undetectable
responses may be attributed to the seven-fold dose reduction relative
to a typical full shot dose of 1 μg of a single gene. Alternatively, these
lower level responses were suppressed in the context of the other
antigens. These results demonstrated that (i) the construct design
strategy is sufﬁcient for genetic immunization, and (ii) within a pool
of seven genes encoding antigens known to hold a range of
immunogenicity levels, the antibody response to the four stronger
immunogens concomitantly stimulated immune responses.
To facilitate broad antigenicity, the seven test genes were sub-
cloned into a second mammalian vector, pCMViUB, which expresses
inserted coding sequences with an N-terminally fused ubiquitin (UB)
subunit. Both the LS and UB fusion constructs were used to assess
humoral immune responses to antigens delivered genetically within a
more complex pool of other ORFs. Each set of seven constructs was
diluted into a mixture 250 other constructs expressing ORFs from
Bacillus anthracis. These spiked LS and UB construct pools were
delivered by gene gun into groups of 10 C57BL/6 mice; the control
group was unimmunized. A booster immunization was given at week
4; pooled sera were analyzed 2 weeks after the boost for speciﬁc
antigen reactivity by ELISA in Figs. 2B and C. The positive titers found
in the pool-immunized mice demonstrate the feasibility of stimulat-
ing antibody responses by immunizing with highly complex pools of
genes. Notably, neither expression vector elicited signiﬁcant titers to
all of the antigens; however, taken together the LS and UB vectors
stimulated responses to four out of the same four antigens found to be
immunogenic without dilution (Fig. 2A). The optimal vector was
antigen dependent. For example, the LS fusion construct generated
the highest titers anti-gD titers while the UB constructs showed
higher PA4 and A33R titers than the LS constructs expressing the same
antigens.
The individual sera titers elicited by mice immunized with the gD
and A27L expressing LS constructs were also determined so as to
facilitate a comparison of the diluted and undiluted genetic inocula
shown in Figs. 2A and B. Importantly, the results plotted in Fig. 3
corroborate the pooled sera data in that differences in response levels
are not linearly proportional to differences in the inoculating dose
(compare Fig. 2A versus Fig. 2B; Fig. 3A versus Fig. 3C; Fig. 3B versus
Fig. 3D). Namely, a 250-fold reduction in the dose of gD and A27
expressing plasmids led to only an approximate 10-fold reduction in
the elicited titers. Responder frequencies were also assessed. Without
dilution, all animals responded (10 of 10 for both gD and A27L), and
even with a 250-fold dose dilution responder frequencies were high
(9 of 10 for gD; 6 of 10 for A27L).
Methods for high throughput plasmid construction
Gene-building techniques based on polymerase chain reactions
(PCR) generate mixtures of molecular species that perfectly or
imperfectly correspond to an intended gene sequence. Standard
cloning procedures enable a single molecule to be isolated and
ampliﬁed. After generating transformants, researchers typically purify
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to identify a bona ﬁde sequence. For the large program presented
here, these cloning and sequence-searching procedures would have
rendered library production timeframe and costs untenable. As an
alternative, we explored using batched recombinant DNAs. Standard
bacterial cloning involves ampliﬁcation of E. coli transformants
carrying a single plasmid species. By contrast, if bacteria transformed
with a mixed population of plasmids are co-cultured, then growth
biases occur as the transformants are unequally ﬁt. Hence, the
ampliﬁed plasmid population may not reﬂect the original molecular
diversity. Our method would be possible if (i) collectively the gene-
building reaction products included all the desired nucleotide
sequence space (and thereby the encoded epitope space) and (ii)
the molecular diversity of any mixed batch of bacteria could bemaintained. In particular, we supposed generating 150 mini-libraries,
each comprised of ∼30 different synthetic ORF products, non-clonally
engineered into the LS and UB vectors.
To investigate how ORF species diversity would drift during
bacterial ampliﬁcation, we conducted the following experiment.
Sixteen different PCR-generated ORFs with known sequences were
built with deoxyuracil (dU) ends and treated with uracil-DNA glyco-
sylase (UDG) to expose 3′ overhangs. These were annealed into the LS
plasmid via a complementary overhang sequence. This method of
inserting DNA into a plasmid is more amenable to a high throughput
protocol since restriction enzymes are not used. ORF sequences do not
need to be individually analyzed to identify and accommodate
internal restriction sites and no ligation reaction steps are needed.
Linkage products were used to transform E. coli and cells were plated
to determine the transformation efﬁciency by counting colonies the
following day. To assess any molecular population drift, the same
experiment was repeated; however, the transformants were not
directly plated. Instead, dilutions that approximated from 106 to 102
transformants were used to inoculate an overnight culture (2 ml).
Aliquots of these stationary cultures were plated and colonies grown.
Plasmids were puriﬁed from selected colonies and sequenced to
determine the identity of the ORF species. These results are
summarized in Table 1. The distribution of the 16 ORF sequences in
the original transformants is shown alongside the distribution of
sequences found in ampliﬁed cells. Inoculation of a culture with as
few as 103 transformants was sufﬁcient to maintain most of the
population's diversity with similar distribution. With only half as
many colonies screened, all but two species in the direct plating were
found in the ampliﬁed cells, and the two lost had shown low
representation even in the original population. This contrasts with the
lost diversity of the culture started with 102 transformants. A
bottlenecking down to largely one ORF species occurred, with either
zero or a single representative of all others. Based on these data, we
inferred that the diversity of a mixed plasmid sample could be
sufﬁciently maintained by inoculating growth cultures with 103 or
more original bacterial transformants.
Construction and pooling of the synthetic cowpox expression library
The coding sequences of the CPV Brighton Red strain were recoded
and organized into 789 overlapping ORFs of ∼500 bp in length as
described in the Materials and methods. ORF size was guided by our
previous studies demonstrating that fragments of ∼200 amino acids
elicit a broader immune proﬁle than do either larger or smaller ones
(Sykes and Johnston, 1999). Each ORF was assembled, and then
product yield was quantitated by ﬂuorometry and veriﬁed for length
and quality by agarose gel analysis. Quantities were normalized andFig. 2. Evaluating immunogenicity of gene pools. (A) In vivo activity of test-antigen-
expressing constructs. A mammalian expression vector (pCMViLS) carrying genes
encoding antigens from cowpox (homologues of VACV A27L, A33R, B5R, and L1R), HSV-
1 (gD), Y. pestis (V antigen), and anthrax (PA4) were biolistically co-delivered into the
ears of a group of 10 C57BL/6 mice (2×1 μg total DNA dose) at weeks 0 and 4. Two
weeks after the boost, sera from the immunized group and a naïve control group were
collected. Reactivities of pooled sera against each speciﬁc antigen were assayed by
ELISA. Log serum dilution factors are plotted against ﬂuorescence units. For ﬁgure
clarity, data on B5R, L1R, and V antigen were not plotted since they were not
signiﬁcantly different from naïve sera. (B) Immune responses stimulated by the leader
sequence fusion constructs within a complex pool of gene-expressing constructs. A pool
of 250 ORFs from the genome of an irrelevant pathogen was spiked with the LS antigen
expression constructs. A group of 10 mice were biolistically immunized (2×1 μg shots)
at weeks 0 and 4 with this complex pool and ORFs. Sera were drawn 2 weeks after the
last boost, pooled, and assayed against each of the four antigens by ELISA. Log serum
dilution factors are plotted against ﬂuorescence-unit readouts. (C) Speciﬁc immune
responses stimulated by ubiquitin fusion constructs within a complex pool of gene
constructs. A pool of 250 ORFs from the genome of an irrelevant pathogen was spiked
with the set of UB expression constructs. Mice (10 per group) were gene-gun
immunized with the mixed inocula (2×1 μg shots) at weeks 0 and 4. Pooled sera were
analyzed and plotted as described in Fig. 1B.
Fig. 3. Individual sera analysis of pools of antigen-expressing test constructs. To discern responder frequencies, the sera from the mice described in Figs. 2A and B were individually
tested by ﬂuorescent ELISA. Reactivities are shown against HSV1 glycoprotein (g)D in sera frommice immunized with the LS test constructs undiluted (A) or inmice immunized with
the test constructs diluted into a pool of 250 irrelevant ORF expression constructs (B). Similarly, VACV A27L reactivity was measured in mice immunized with the LS test constructs
undiluted (C) or diluted into the same pool of 250 irrelevant expression constructs (D).
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mixtures of ORFs were annealed into both pCMViLS and pCMViUB
vectors and used to transform E. coli. An aliquot of the each of the 150
transformation mixes was plated to determined transformation
frequency. If at least 104 original transformants were counted, then
the remaining culture (2 ml) was used to inoculate a growth cultureTable 1
Validating CPV library ampliﬁcation scheme.
ORF Direct plating % of total ∼106 inoc % of total ∼105 inoc
Sequence 1 1 1.3 1 3.3 3
Sequence 2 2 2.5 0 0 4
Sequence 3 1 1.3 1 3.3 1
Sequence 4 13 16.3 4 13.3 0
Sequence 5 5 6.3 4 13.3 0
Sequence 6 4 5 1 3.3 5
Sequence 7 12 15 6 20 1
Sequence 8 13 16.3 3 10 3
Sequence 9 5 6.3 2 6.7 0
Sequence 10 4 5 2 6.7 5
Sequence 11 2 2.5 1 3.3 0
Sequence 12 11 13.8 2 6.7 1
Sequence 13 2 2.5 0 0 0
Sequence 14 1 1.3 0 0 2
Sequence 15 1 1.3 3 10 1
Sequence 16 3 3.8 0 0 5
Total clones sequenced 80 30 31(100 ml). This corresponds to 10-fold more inoculating bacteria than
we demonstrated were required to maintain diversity. Otherwise, the
transformation was repeated. Cells were harvested at mid-log phase
for plasmid puriﬁcation. All 150 prepared plasmid preparations were
quantitated and assessed by restriction digest to conﬁrm DNA quality
and to visualize range of inserts.% of total ∼104 inoc % of total ∼103 inoc % of total ∼102 inoc % of total
9.7 5 15.2 2 4.9 0
13.0 7 21.2 2 4.9 8 14.8
3.2 2 6.1 1 2.4 43 79.6
0 1 3.0 2 7.3 0
0 0 0 1 2.4 1 1.9
16.1 2 6.1 3 7.3 0
3.2 4 12.1 5 12.2 0
9.7 1 3.0 9 22.0 0
0 0 0 5 12.0 0
16.1 4 12.1 4 7.6 1 1.9
0 0 0 0 0 0
3.2 1 3.0 2 4.9 0
0 0 0 1 2.4 0
6.5 3 9.1 0 0 0
3.2 2 6.1 3 7.3 1 1.9
16.1 1 3.0 1 2.4 0
33 41 54
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Table 2
Rank ordering of the 25-X, 25-Y, and 25-Z sub-libraries by protection score.1–4
1Shaded groups were carried into analysis for antigen identiﬁcation.
2Groups in bold were statistically different from controls at pb0.05.
3Groups in bold italics showed a statistical trend as different from controls at pb0.10.
4Groups in X library were statistically analyzed to remove those groups showing enhanced disease relative to negative controls. By contrast, the Y and Z libraries were statistically
analyzed to identify those groups showing extended survival relative to the negative controls.
103A. Borovkov et al. / Virology 395 (2009) 97–113Screening ORF pools as vaccines in challenge-protection assays
To prepare the inocula, the LS and UB plasmid preparations
carrying of the same ORF pools were mixed in equal proportion.
These 75 DNA samples were precipitated onto gold microprojec-
tiles and biolistically delivered into C57BL/6 mice. Two negative
control groups were immunized with a plasmid expressing green
ﬂuorescent protein (GFP) or naive. A positive control group was
immunized with of a sublethal dose of live CPV. Another group was
genetically immunized with the CPV homologues of the VACV 4-pox
vaccine constituents A27L, A33R, B5R, and L1R. Animals were
boosted twice, at weeks 3 and 8. At week 14 post-prime, the animals
were i.t. challenged with one lethal dose (1 LD100) of CPV. This dose
was deﬁned as the lowest dose of virus required to kill 100% of the
control animals in a titration experiment conducted 2 weeks earlier
with the same viral stock. Challenges were cascaded as three sub-
experiments X, Y, and Z, with controls in each set. Animal survival
was checked at approximately 12-h intervals and data recorded
twice daily due to the rapid course of the disease. The hours sur-
vived by each mouse within all 75 experimental and control groups
were analyzed by two methods. First a single value was also
assigned to each group as its protection score by calculating an
average survival time. This was obtained by multiplying the time
value (in hours post-challenge) at an observation by the number of
mice alive at that time value. This total survival time value was
divided by the starting number of mice to derive an average group
survival time, which would be the group's protection score. The dataFig. 4. ELI screen protection scores. Expression libraries built from these ORF pools were
represented the complete library andwas designated X1-X25 (A), Y1-Y25 (B), or Z1-Z25 (C).
and monitored twice daily for 21 days. A protection score for each of the 75 groups was
comprised of the cowpox homologues of the 4-component vaccinia vaccine candidate (4-po
irrelevant construct. Naïve and low-dose cowpox immunized groups are negative and positi
are shown as gray bars. Note that for sets Y and Z, groups with signiﬁcant protection are sho
The 95% conﬁdence interval relative to the irrelevant vaccine controls is shown. Nonparame
Risks signiﬁcantly greater than the average odds-ratio were considered as candidates. All
prevent bias due to non-normal data distribution. Due to space consideration, survival plotfrom the two negative control groups were combined into a single
control group for data analyses. These data are plotted for all groups
within the X (Fig. 4A), Y (Fig. 4B), and Z (Fig. 4C) libraries. A line is
drawn at the lower (X plot) or upper (Y and Z plots) values of the
90% conﬁdence interval. The protection scores were used to rank
order each group within the three libraries; both score and rank are
displayed in Table 2. As a second analysis, a Mantel–Haenszel
survival curves (Prism 4.0; Graphpad Software, San Diego, CA) were
determined in order to calculate p values and identify groups with
signiﬁcantly extended times to death. The Y and Z groups shown in
bold were signiﬁcantly protected compared to the negative controls
(pb0.05) and those in bold italics had a trend towards protection
(pb0.10). There were no signiﬁcantly protective groups from the X
library; therefore, we could not select any positives. In general, mice
in the X library lived longer than mice in the Y and Z libraries,
suggesting a weaker challenge was administered to the X set.
Nonetheless, we could statistically eliminate eight of the groups as
negative. Namely, the groups shown in bold (pb0.05) or bold italics
(pb0.10) succumbed more quickly than the negative controls. Since
the remaining 17 could not be eliminated from the screen, all of
these groups were included in our next round of screening and are
shaded in Table 2. By contrast, several groups in the Y and Z sets
displayed statistically improved survival and all but one of these
rank-sorted as the top seven protective groups by scoring. We
selected the top seven groups of the Y and Z libraries and one rank-
outlying but statistically protective group Y-14 to carry forward.
These groups are shaded in Table 2. In the Z library, another threeevaluated in a murine pulmonary challenge-protection assay. Each set of 25 groups
C57BL/6mice (10 per group) were challenged i.t. as described inMaterials andmethods
determined and plotted against controls. A27L/A33R/L1R/B5R is a mixed inoculum
x). The eGFP plasmid expresses a codon-optimized green-ﬂuorescence gene used as an
ve controls, respectively. Groups signiﬁcantly different from the negative control group
wn in gray. By contrast for set X, groups displaying enhanced disease are shown in gray.
tric tests using the Mantel–Haenszel log-rank test showed identical or nearly so values.
survival data were considered both parametrically and nonparametrically in order to
s are not shown.
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not carry these forward because they were not signiﬁcantly
different from the controls by survival curve analysis. Since the
ORFs comprising the selected X, Y, and Z pools are known, a matrix,
overlap analysis was performed. All ORFs commonly found within
the three lists of ORFs comprising the selected X, Y, and Z pools were
identiﬁed. This can be envisioned as a triangulation of positive X, Y,
and Z coordinates and indicated 48 ORFs as possibly responsible for
conferring the observed level of protection. This output is a function
of the number of selected groups and the percent of loci assigned
ORFs within the virtual cube that was used for arraying. If we
assume each pool contains no more or less than one protective ORF,
the anticipated number of protective ORFs among the 48 intersec-
tions should approximate the smallest number of groups selected
from any one library.
None of the CPV homologues (CPV 165, CPV 172, CPV 204, and CPV
106) of the VACV 4-pox inoculum (A27L, A33R, B5R, and L1R) were
identiﬁed by our analysis of the survival data. Consistent with this
result, the CPV 4-pox homologues did not show protection in the
model even when delivered directly as an undiluted vaccine (Figs. 1
and 4). Among the 48 inferred candidates, ﬁve do not have variola
virus homologues, and one of these is not found in variola or vaccinia.
These ORFs may warrant investigation as CPV or MPV candidates;
however, we chose to concentrate our most immediate efforts on
the ORFs most likely to comprise a smallpox vaccine. Among the
remaining ORFs, several were found to be different portions of the
same gene, such that 13 of the ORFs correspond to only ﬁve genes.
Furthermore, these ORFs have overlapping sequences. We suggest
this indicates that the protection screen sorted the coding sequences
non-randomly. Fig. 5 displays a mapping of these ORFs with respect to
their derivative genes. Analysis also established that CPV 008 and CPV
227 are two independent loci carrying identical genes. The ELI screen
identiﬁed both of the gene duplicates and was able to identify the
same two overlapping ORFs within them. This redundancy indicates
that a complete screening of the library was accomplished. With the
ﬁnal removal of one of these chromosomal duplicates, we arrived at a
shortlist of 41 ORFs, and 36 of these were selected to test as
individually delivered vaccine candidates in the CPV-C57BL/6
protection assay.Fig. 5.Multiple ELI-selected ORFs map to the same genes. The genomic locations of the
36 individual CPV ORFs selected by matrix analysis of the protection assay results were
determined. Sets of ORFs were identiﬁed that correspond to distinct but overlapping
regions of the same gene. These genes are shown, represented as bold bars; the ORFs
are drawn below the corresponding gene with its nucleotide endpoints indicated.Identiﬁcation of cowpox ORFs that individually confer protection against
a lethal pulmonary challenge
The 36 CPV gene fragments identiﬁed in the ELI screen were
synthetically regenerated and inserted into the LS and UB plasmids
(Fig. 6). These ORF-expressing constructs were now clonally puriﬁed
by standard bacterial transformation and colony growth. Both UB and
LS expression constructs for each ORF were isolated and sequenced to
identify bona ﬁde DNAs. UB and LS constructs carrying the same ORFs
were mixed at equal molar ratios. CPV 073 fragments a and b were
combined since they are derived from the same gene and shared only
minimal overlap (15 nucleotides) such that combining them would
not skew epitope doses. The DNAs were precipitated onto gold
microprojectiles, as before, and biolistically delivered into groups of
10 C57BL/6micewith a Helios gene gun (BioRad, Inc.). Control groups
were immunized with a low-dose infection of live virus (positive), an
irrelevant gene vaccine from B. anthracis (negative), or an unimmu-
nized (negative). Animals were immunized with 2×1 μg shots at
weeks 0, 3, and 8. The test groupswere randomly split into two phases
for the challenges. At week 13 or 14 post-prime, mice were challenged
by i.t. route with a lethal dose of CPV and then monitored at 12 h
intervals for 14 days. Deaths were recorded and survival hours
tabulated. Average survival hours for each group were calculated and
compared to that of all test samples. The protection scores are
graphed in Figs. 6A and B, and the 95% conﬁdence interval is
delineated with a dotted bar. As before, the CPV homologues of the
VACV 4-pox inoculum did not confer signiﬁcant protection in this
murine-cowpox model of pulmonary disease; however, the live virus
vaccine conferred strong protection. The ORFs tested in each phase
were also combined and delivered into mice as a pooled inoculum.
Neither of these collections of protective and non-protective ORFs
conferred signiﬁcant protection. By contrast, nine of the individually
delivered ORFs did confer C57BL/6 signiﬁcant protection against a
lethal pulmonary CPV infection.
Analysis of vaccine candidates
In Table 3, the identities of all nine cowpox genes selected as
candidates are presented alongside the corresponding VACV and
VARV genes. Known or putative functions are indicated based on
homologies to previously characterized proteins; two ORFs encode
hypothetical proteins. To conﬁrm these protection results, a new
similarly designed experiment was initiated. CPV 227c was left out of
this round because it is a putative host range factor (Antoine et al.,
1998) and therefore may not be broadly useful against the poxvirus
family. Homologues, however, may be useful as an orthopox-speciﬁc
antigen. The remaining eight plasmid constructs expressing the ORFs
displaying protection in the ﬁrst experiment were again precipitated
onto gold and prepared for biolistic immunization of C57BL/6 mice
(12 per group). Controls were similar to the previous experiments
except the irrelevant ORF was a gene encoding a protective chimeric
antigen from an irrelevant pathogen (Y. pestis F1-V). A similar
immunization regimen was carried out, and at week 13 post-prime
the mice were i.t. challenged with 1 LD100 of CPV. The survival results
of the test groups were analyzed against survival of mice immunized
with the irrelevant gene vaccine, F1-V, and plotted in survival graphs
(Fig. 7A). Using the Mantel–Haenszel survival curve analysis, p values
were calculated and shown above each plot. All but two of the
candidates (CPV 030 and CPV 225) showed reproducibly signiﬁcant
protection (p values of ≤ 0.027).
In another experiment, constructs expressing the nine ORFs
selected from the ELI screen were pooled and biolistically delivered
into C57BL/6 mice using an abbreviated regimen relative to the prior
experiment. For comparison, a group was immunized with the CPV
homologues of 4-pox. A lethal i.t. challenge was administered 6 weeks
post-prime, and survival was monitored. These results are plotted in
Fig. 6. ORFs selected in the ELI screen were individually tested as vaccines in the challenge-protection assays. Analyses of the protection scores identiﬁed a shortlist of ORFs to further test
as single-gene inocula. Groups of C57BL/6mice (10 per group)were immunizedwith one plasmid, without adjuvant, and then i.t. challengedwith a previously titrated lethal dose of CPV.
Differences in cumulative survival hourswere compared using the difference inmeans between control samples and test samples. Conﬁdence intervals of the resulting difference inmeans
(control minus test) that did not include 0 were considered signiﬁcant and are colored grey. The dotted bar displays the upper limit of the 95% conﬁdence interval for the test groups.
Table 3
Bioinformatic analysis of conﬁrmed protective CPV candidates.
CPV ORF Vaccinia homologue Variola homologue Function or homology Survival1 (p value)
CPV 0030a C6L D9L Hypothetical protein 0.013
CPV 0066a F16L C20L Hypothetical protein 0.004
CPV 0097b G7L H7L Core protein 0.027
CPV 0100a G9R H9R Myristoylation site, trans-membrane protein involved in entry/fusion 0.0006
CPV 0110a J5L L5L Myristoylation site, trans-membrane protein of unknown function 0.001
CPV 0120f D1R F1R mRNA capping enzyme; termination and initiation factor 0.025
CPV 0171a A32L A35L GTP-ATPase, DNA packaging, virion assembly 0.003
CPV 0225a C3L G4R Tumor necrosis factor receptor (TNFR) domain, binds secreted complement C3b/C4b 0.490
CPV 0227c C9L B19R Ankyrin-like repeats, host range and tissue tropism, pathogenesis n.d.2
1 p values were calculated by a Mantel–Haenszel log-rank survival curve analysis.
2 In the ﬁrst challenge-protection assay, CPV 0227c conferred protection above the 95% conﬁdence interval, but it was not included in the conﬁrmatory study.
105A. Borovkov et al. / Virology 395 (2009) 97–113
Fig. 7. Conﬁrmation of protective capacities of new C57BL/6 vaccine candidates. (A) Survival of mice immunized with individual CPV gene vaccine candidates and challenged in an
independently conducted protection experiment. Mantel–Haenszel survival plots (Prism; GraphPad Inc., La Jolla, CA) display differential survival rates of mice immunized with one
of eight CPV vaccine candidates relative to mice immunized with a gene expressing an irrelevant vaccine antigen, F1-V. The calculated p values for each candidate are provided above
the corresponding survival curve. Ten mice per group were used; an a posteriori power analysis indicates six mice per group were needed to observe differences in cumulative
survival of less than 10% at 95% conﬁdence and 80% power. (B) Evaluation of a pool of the top nine ORF candidates in the vaccine assay. Mice (15 per group) were immunized with the
ORFs identiﬁed in the ELI screen alongside positive and negative controls: live vaccine and naïve mice, respectively. Survival results following a lethal CPV challenge are displayed as
Mantel–Haenszel plots. Data were analyzed as above.
106 A. Borovkov et al. / Virology 395 (2009) 97–113Fig. 7B along with positive (live VACV) and negative (naive) control
groups and show that the pool of nine CPV ORFs was partially
protective in the C57BL/6 strain (p = 0.003), whereas co-delivery of
homologous CPV 4-pox genes was not.
Host immune responses to candidate vaccine antigens
A preliminary investigation of the immunogenicity of the nine
ORFs as gene vaccines was conducted. Since no pre-screen for
immunogenicity was performed, the level or type of B and T cellimmune responses elicited by these ORFs would be unknown. Mice
were individually gene-gun immunized with the nine ORFs and then
boosted with either DNA or protein as described in Materials and
methods. Blood and spleens were harvested 10 days later. Antibody
responses to the antigens were assessed in ELISAs or immunoblots by
measuring reactivity of sera to peptides or protein antigen, respec-
tively. These antibody results, summarized in Table 4, indicate that all
of the tested candidates stimulated production of antigen-speciﬁc
antibodies, as measured by one or both of the assays. For comparison
of sera reactivities to know orthopox immunogens, the CPV
Table 4
Summary of antibody responses to CPV vaccine candidates.
Candidate Mouse no. ELISA Immunoblot
Responders Titer Responders
CPV 030a 1 3/4 800 6/6
2 800
3 0
4 0
5 ND
CPV 066a 1 1/4 0 3/6
2 0
3 0
4 1600
5 ND
CPV 097b 1 4/5 400
2 200
3 1600
4 6400
5 0
CPV 100a 1 3/4 N6400
2 0
3 1600
4 1600
5 ND
CPV 110a 1 2/4 6400 5/6
2 0
3 0
4 400
5 ND
CPV 171a 1 ND 6/6
2
3
4
5
CPV 225a 1 5/5 3200
2 12800
3 3200
4 6400
5 800
Fig. 8. T cell responses elicited by orthopox subunit vaccine candidates. (A) Survey of
peptide-stimulated T cell responses of mice individually immunized with the CPV
vaccine candidates. Splenocytes from immunized mice were harvested and stimulated
with a peptide pool comprised of 20-mers tiling the ORF-encoded product. IFN-γ
release of activated T cells was measured by ELISpot. Data are presented as the number
of antigen-speciﬁc spot-forming units (SFU) per million splenocytes. SFU counts were
adjusted for background by subtracting the number of spots in wells containing
unstimulated splenocytes (no antigen). Triangular icons represent splenocyte results
from individual mice. Black bars display group mean SFUs. Error bars reﬂect the
standard deviation between quadruplicate assay wells. (B) Comparison of peptide-
stimulated T cell responses of mice immunized with a CPV ORF or a CPV homologue of
4-pox vaccine candidates. Splenocytes from immunized mice were harvested and
stimulated as above. CPV homologues of the VACV 4-pox genes are as follow: CPV 165a/
c (VACV A27L); CPV 172 (VACV A33R); CPV 106 (VACV L1R); and CPV 204 (VACV B5R).
(C) T cell cytokine release levels of candidate-immunized mice in response to protein–
antigen stimulation. Splenocytes were stimulated with 20 μg of recombinant protein,
except for CPV 100a-immune cells which were stimulated with peptide. IFN-γ release
of activated T cells was measured by ELISpot. Data are presented as the number of
antigen-speciﬁc SFU per million splenocytes. SFU counts were adjusted for background
by subtracting the number of spots in wells containing unstimulated splenocytes (no
antigen). Icons represent splenocyte results from individual mice. Black bars display
group mean SFUs. Error bars reﬂect the standard deviation between quadruplicate
assay wells.
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(VACV A33R) were also expressed in E. coli and used to evaluate sera
from mice immunized with the corresponding mammalian expres-
sion constructs by immunoblot. The relative number of animal
responders within a group was similar between the new candidates
(6/6, 3/6, 5/6, and 6/6) and two 4-pox genes (2/4 for CPV 165 and 4/
4 for CPV 172).
T cell responses were assessed by measuring the number of cells
that secreted interferon-γ (IFN-γ) in ELISPOT assays. CD4+ and CD8+
T cell responses to the nine new CPV antigens and homologues of the
4-pox antigens were determined by enumerating the number of
splenocytes harvested from immunized mice stimulated with either
peptide or protein antigens. Recombinant protein puriﬁed as inclusion
bodies or overlapping peptides synthesized to span the protein
sequence were used. The graphs in Figs. 8A and B display the number
of T cells from individual immune mice that secreted IFN-γ in
response to peptide antigen, and group averages, from two indepen-
dently conducted experiments. The experiment displayed in Fig. 8B
includes the homologues of the VACV vaccine candidates, CPV 165
(A27L), CPV 172 (A33R), CPV 106 (L1R), and CPV 204 (B5R) for
comparison. In Fig. 8C, ELISpot analysis of IFN-γ released from
splenocytes stimulated with recombinant protein or peptides (CPV
100a). In general, protein antigen stimulated more T cells than did the
sets of peptide antigen. Immune T cells speciﬁcally responded to all
nine CPV antigens, as either peptide or protein.
Discussion
Non-variola models of smallpox, if not perfect (Precopio et al.,
2007), are necessary because humans are the only variola host andnatural disease is eradicated. Since efﬁcacy against smallpox cannot
be directly tested, a practical approach to subunit discovery is to
identify a panel of protective antigens that are most likely to be
broadly effective in different hosts and against different orthopox-
viruses. To date, several subunits have been identiﬁed and character-
ized as protective predominantly using a vaccinia-BALB/c mouse
model of disease. Our rationale for further antigen discovery was the
observation that the VACV 4-pox subunit inoculum is not protective in
another mouse strain, C57BL/6. By accumulating more antigens, we
would be prepared for candidate attrition during the vaccine
development process.
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cowpox virus as vaccines was conducted in a natural host. To our
knowledge, this is the ﬁrst functional screening of a complete
synthetic proteome in vivo. Expression library immunization assumes
that individual antigens can be productively immunogenic in the
presence of others. This parallels the complexity of a live or killed
whole-pathogen vaccine or a pathogen infection, in which the
immune system is exposed to a mixture of many foreign components.
All antigens are not anticipated to be universally detected in this
context but since many can be detected, we have a means of iden-
tifying useful immunogens from any class of protein, encoded by any
known or unknown gene.
Building all the coding sequences as codon-optimized versions
allowed us to normalize antigen expression levels for the screen;
placing each ORF in two mammalian expression vectors allowed us to
dually target the antigens intracellularly to facilitate broad immune
presentation. The relevance of any viral component to disease pro-
tection was evaluated in a vaccine assay. All ORF expression cons-
tructs were delivered into different groups of mice, and all these
genetically immunized animals were challenged with a lethal
pulmonary dose of CPV. Survival readouts were used to establish
the value of the ORF inocula. From an original library of 789
components, an initial shortlist of 41 ORFs was honed.
This shortlist holds a number of interesting features. The gene
sources of these ORFs suggest that the screen was both non-random
and complete. In particular, ﬁve genes were the source of 13 screen-
selected ORFs, including a pair of gene duplicates. CPV 008/227 ORF
carries an ankyrin repeat motif, indicating a region of protein–
protein interaction. This class of proteins has been shown to inﬂu-
ence viral pathogenesis, host range, and tissue tropism (McFadden,
2005; Shchelkunov et al., 2000). CPV 120, which is the source gene
of three different ORFs on the shortlist, is homologous to VACV
protein D1R. It is transcriptional termination factor VTF (Jing et al.,
2005) and a subunit of the mRNA capping enzyme (Myette and
Niles, 1996). Within D1R, a strong human CD8 epitope has been
identiﬁed (Jing et al., 2005) and is one of only a few viral proteins
recognized by CD8+ T cells across MHC and species boundaries
(Oseroff et al., 2008). The other three genes that were repeatedly
identiﬁed do not encode proteins with high homology to any
characterized protein domains in the BLAST databases. The iden-
tiﬁcation by protection assay of more than one region within the
same protein may indicate that these are immunoprevalent anti-
gens, potentially serving as rich sources of protective epitopes.
Although no function is known, CPV 073 is the homologue of the
VACV and VARV gene E6R, which is highly conserved in all currently
sequenced poxviruses. This feature would be anticipated for a
broadly cross-protective antigen. CPV 066 and CPV 134 correspond
to VACV genes F16L and D13L, and to VARV genes E16L and N3L,
respectively. A number of the ORFs indicated by the screen have no
sequence homology with any known protein or protein domain and
therefore would have been difﬁcult to identify as vaccine candidates
by any rational design program. These results corroborate our
original hypothesis that a function-based screen for vaccines might
reveal candidates that would not have been informatically identiﬁed
with current algorithms.
Consistent with the lack of protection observed by the 4-pox
inoculum in C57BL/6 mice, the CPV homologues of these VACV
envelope genes (A27L, A33R, B5R, and L1R) are not found on the ELI
shortlist. The other antigens previously described as protective in the
VACV or ECTV models were also not found. It is possible that these
antigens do not translate to the CPV as protective antigens. Alter-
natively, they may indeed hold some protective capacity for CPV but
at a level not detectable in our assay, in which pooled genes were
delivered without adding adjuvants or immunomodulators.
From the shortlist, 36 ORFs were tested as individual genes in the
protection assay. Nine were found to be protective, and eight of theseORFswere selected for retesting. CPV 227was not retested at this time
because its VACV homologue, C9L, is known to be a host range factor.
This suggests that it may be relatively unconserved and therefore not
cross-protective against other poxviruses nor protective in other
animal models of disease, unless homologues are used. In the second
independently conducted challenge-protection assay, six of eight
tested candidates were conﬁrmed as conferring signiﬁcant levels of
protection. We based our selection of ORFs on identifying those that
reside in three positively scored inocula: 1 X, 1 Y, and 1 Z. Given the
number of groups calculated as positive from each X, Y, and Z library
(17, 8, and 7, respectively) and assuming each selected pool carries
one and only one protective antigen, approximately seven positive
ORFs is predicted.
Five of the nine ORFs initially found to be protective encode
homologues of proteins known to be expressed within the IMV
particles of VACV or VARV (CPV 30, CPV 097, CPV 100, CPV 110, and
CPV 120) but only two of these (CPV 100 and CPV 110) are envelope
proteins (Chung et al., 2006). Little is known about the location of
hypothetical protein CPV 030. CPV 097 (VACV G7L) is homologous to a
VACV virion structural core protein (Szajner et al., 2003). Both CPV
100 and CPV 110 carry consensus myristoylation sites. This lipid
modiﬁcation is typically involved in directing and anchoring proteins
to membranes and indicates involvement in membrane targeting and
signal transduction (Boutin et al., 1997). The previously identiﬁed
VACV protective antigen L1R is also amyristoylated protein (Wolffe et
al., 1995). The VACV homologue of CPV 100 (VACV G9R) is an
essential component of the entry/fusion complex (Ojeda et al., 2006a,
2006b). The function of CPV 110 (VACVJ5L) is unknown but it appears
to be essential for VACV multiplication (Zajac et al., 1995). CPV 120 is
VACV D1R as described above. Among the remaining ORFs, the only
other membrane protein is CPV 225. CPV 225 (VACV C3L) carries
homology to a secreted TNF receptor, Crm-B (Alcami et al., 1999).
Secreted TNFRs have been shown to inﬂuence host immune responses
to VACV. These immune modiﬁers are exposed to both intracellular
and extracellular environments. VACV deletion of its homologue of
CPV 225 led to decreased virulence (Thornburg et al., 2007). No
function has been implicated for CPV 066. The VACV homologue of
CPV 171 (VACV A32L) is a GTP-ATP-binding protein believed to be
involved in DNA packaging and virion assembly (Afonso et al., 2000).
In sum, a cross-section of both surface and non-surface proteins was
identiﬁed, which suggests that both categories of viral components
may serve as vaccine targets.
We screened for individually protective ORFs; we did not screen
for combinations of ORFs that may additively or synergistically
provide signiﬁcant protection. Although we tested the top nine
candidates as a mix, each ORF was identiﬁed from different sub-
libraries and tested for its capacity to individually protect. We
consider the possibility that some other candidates within the list of
screen-selected ORFs may require the context of one or more com-
ponents of their original sub-library to confer protection. For example,
genes CPV 073 and CPV 134 were each identiﬁed twice in the ELI
screen, in which the ORFs were delivered as mixed inocula of ∼30
other ORFs. When these two ORFs were tested individually, they did
not confer protection. CPV 073 and CPV 134 may require immuno-
logical help or speciﬁc combination with another gene(s) in order to
be protective. By contrast, the other genes that were the source of
multiple screen-selected ORFs did confer signiﬁcant partial protection
as individual inocula. Since the nine candidates were randomly
assembled, with respect to immune cooperation, it is not surprising
that they are not synergistic.
All nine molecular vaccine candidates selected in the screen were
shown to speciﬁcally stimulate both antibody and T cell immune
responses. This is consistent with previous work that suggests both
humoral and cellular components of adaptive immunity are impor-
tant against poxviruses (Ferrier-Rembert et al., 2007; Smith and
McFadden, 2002). We assayed responses against the antigen itself
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the ORF's immune potential due to differences in location or stoi-
chiometry within the virus. Upcoming studies will characterize these
responses to virus and also evaluate responses stimulated against
these antigens upon live virus immunization or infection.
Immunity in humans and mice elicited by live virus is character-
ized by the presence of circulating antiviral antibodies and relatively
high frequencies of viral speciﬁc memory T and B cells (Demkowicz et
al., 1996; Hammarlund et al., 2003; Xu et al., 2008). It is not clear
whether these same effectors must be elicited by any successful
vaccine or rather that other mechanisms might provide immunity by
an alternative route. The differing performance of the 4-pox inoculum
in the Th2-biased BALB/c and Th1-biased C57BL/6 murine models
will enable a unique dissection of immune activities associated with
protection and non-protection. Whether any of the new candidates,
individually or as a pool, also protect BALB/c mice still needs to be
determined. Either way, comparison of the immune responses elicited
by these inocula in the two genetically diverse host strains may
suggest unique correlates of protection.
In conclusion, we searched an expression-normalized synthetic
cowpox gene library for sequences that encode protective antigens.
Without pre-screening, all sequences were directly evaluated in an
optimized animal model for their utility as a vaccine candidate. As is
typically observed for subunit vaccines, these single antigens confer
partial, not strong, protection. Learning to productively combine the
subsets of the nine new orthopox antigens and existing antigens
would provide the opportunity to stimulate a breadth of immunity
that even a live vaccine might not elicit. The wisdom of emplacing a
smallpox vaccination program against a possible biothreat event
continues to be controversial (Wiser et al., 2007). If such a policy
were ever to be adopted, a subunit-based product is likely to be
preferred. Meanwhile, we envision more immediate, non-threat uses
of an orthopox vaccine against a number of emerging poxviral
diseases.
Materials and methods
Gene recoding, oligonucleotide design, and oligo synthesis
All 233 protein coding CPV genes annotated in GenBank were
extracted from the genomic database. The coding sequences were
redesigned for optimal mammalian translation based on the codon
usage of a set of highly expressed mammalian genes from EMBOSS.
Using codon adaptation index (CAI) criteria, genes were converted to
sequences with CAI values of greater than 0.8. The predicted new
genes were electronically organized into 789 open-reading frames
(ORFs) of approximately 500 bp in length. The 81 CPV genes of less
than 500 bp were represented as full-length fragments. The 152
longer genes were split into smaller fragments that overlap by at
least 50 bp. ORF names for subgenes were assigned using the
corresponding gene name followed by progressive lettering. These
ORF sequences were used to predict two sets of oligonucleotides
(oligos) for synthetic gene assembly: gene-building oligos (GBOs)
and gene ampliﬁcation primers (GAPs). GBO sequences were
obtained by partitioning both DNA strands of each ORF into sets of
60 nt fragments, which overlapped by 30 nt. GAPs were designed as
Tm-matched primer pairs for each ORF. The GAPs consisted of two
regions: common and gene speciﬁc. All forward GAPs started with
TATAGGCGGAAGCGGATTG and all reverse with GTGGGAGGGAG-
GTTAGGT followed by gene-speciﬁc sequences. All GAP and GBO
oligonucleotides were synthesized in-house on a MerMade-192
oligonucleotide synthesizer (BioAutomation, Dallas, TX) using stan-
dard phosphoramidite chemistry and used after desalting without
any additional puriﬁcation. All oligonucleotides were normalized by
dilution to 50 μM with 10 mM Tris–HCl, pH 7.5, and stored at
−80 °C.Synthetic gene assembling and evaluation
GBOs were diluted to 5 μM and equal volumes (5 μl) of each oligo
were mixed together as 233 separate pools, each comprised of the
oligos for assembly a single ORF. Individual ORFs were assembled
from these pools in a three steps: (i) oligo assembling, (ii) ORF
ampliﬁcation, and (iii) attachment of dU-rich region. Assembling
reactions were performed by mixing 5 μl of individual GBO pools (8 to
35 oligos/pool) with 1 μl of 10 mM dNTPs, 5 μl of 10× Taq PCR with
MgCl2 buffer (Promega), and 0.5 U Taq polymerase (Promega) in total
volume of 50 μl. The mixture was incubated at 95 °C for 1 min,
followed by 35 cycles of incubations at 94 °C for 1 min, 50 °C for 1 min,
72 °C for 2 min, and ﬁnal extension at 72 °C for 5 min. For ORF
ampliﬁcation, 1 μl of an assembly reaction wasmixedwith 1 μl of 1 μM
forward and reverse GAPs, 0.2 μl of 10 mM dNTPs, 1 μl of 10× Taq PCR
with MgCl2 buffer (Promega), 0.1 U Taq polymerase (Promega) in
total volume of 10 μl. The mixture was incubated at 95 °C for 1 min,
followed by ﬁve cycles of incubations at 94 °C for 1 min, 50 °C for
1 min, 72 °C for 2 min, 20 cycles of 94 °C for 1 min, 64 °C for 1 min,
72 °C for 2 min, and ﬁnal extension at 72 °C for 5 min. Next the PCR-
generated products were extended with uracil containing sequences
by adding 90 μl of a master mix composed of 1× Taq PCR with MgCl2
buffer, 1 mM dNTPs, 250 nM universal dU forward (5′AGUAGUA-
GUAGUAGUGGTATAGGCGGAAGCGGATTG3′) and reverse (5′AUGAU-
GAUGAUGAUGAUGTGGGAGGGAGGTTAGGT3′) primers, and 5 U of
Taq polymerase and performing 20 cycles of incubation at 94 °C for
1 min, 55 °C for 1 min, 72 °C for 2 min, and ﬁnal extension at 72 °C for
5 min. The gene products were evaluated by agarose gel electropho-
resis and quantiﬁed by PicoGreen assay according to the manufac-
turer's protocol (Invitrogen). A random set of PCR products was
sequenced directly without cloning to assess ﬁdelity of assembly. All
base calls corresponded to the designed sequence, which demon-
strated that as a population themolecules displayed the intended ORF.
This indicated predominantly proper gene assembling and the
absence of major rearrangements, deletions, insertions, or duplica-
tions. To evaluate uniformity of the generated products, types and
frequencies of the aberrations several independently assembled genes
were sequenced after cloning into pCR3.1 cloning vector. Approxi-
mately half of the analyzed clones carried perfect sequences. The
remaining half predominantly carried single nucleotide deletions and
insertions which would encode partial products.
Design and arraying of ORFs into pools
The complete CPV library of 789 new ORFs were randomly arrayed
into 25 pools of 30–32 ORFs each, such that each ORF was resident in
only one pool. The same ORFs were re-arrayed into 25 new pools two
more times to obtain three complete library sets, designated X, Y, and
Z, and 75 pools. After all 789 ORFs were generated, they were
quantiﬁed using picogreen reagent (Invitrogen) following the manu-
facturer protocol and normalized to 1 μM. Normalized ORFs were
robotically pooled into the 75 groups, and aliquots were used for
constructing plasmid sub-libraries. Remaining ORF sample was stored
at −80 °C.
Cloning PCR-generated products
Two mammalian expression vectors pCMViLS and pCMViUB
(Sykes and Johnston, 1999) were to provide expression of each ORF
with both an N-terminal secretory leader (LS) and as ubiquitin
subunit (UB) fusion, respectively. The two vectors were prepared for
by ligation of single-stranded dU complimenting adapters onto the
restricted BglII and HindIII recognition sites. In particular, each
plasmid (10 μg) was digested with the corresponding enzymes,
dephosphorylated, and gel puriﬁed. Next, 5′ phosphorylated BglII
(GATCTGAGTAGTAGTAGTAGT) and HindIII (AGCTTAGATGATGATGA-
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ends in 50 μl of 1× T4 ligase buffer with 50 U of T4 ligase at 15 °C
overnight using 75-fold molar excess of the adapters. After the
reaction, unligated adapters were removed by gel puriﬁcation. The
resulting vector was precipitated with ethanol and resuspended in TE
at 1 μg/ul.
Prior to incubating with the prepared vectors, 1 μg of dU ﬂanked
PCR products was incubated in 50 μl of 1× UDG Buffer (NEB) with
10 U of uracil-DNA glycosylase (UDG). After incubation for 45 min at
37 °C, DNA was precipitated with ethanol, resuspended in 5 μl of
water, and mixed with the prepared vectors at 1:3 plasmid to insert
molar ratio in 10 μl of water. Insert was annealed to the vector by
sequential incubation of the mixture at 65 °C, 37 °C, and room
temperature for 10 min and then directly used for transformation of
chemically competent Escherichia coli (DH10b) cells (Invitrogen).
Expression immunization library construction and DNA preparation
Small aliquots of the primary transformants from the dU annealing
reaction were plated onto LB agar, grown overnight, and used to
determine complexity of the 75 pool libraries. The remaining cells
were inoculated into 2 ml LB/Amp culture and grown at constant
agitation at 37 °C for 4 h. Then the entire culture was used for
inoculation of 100 ml LB/Amp, which was grown at 37 °C until mid-
log phase (∼1 OD660). Then cells were harvested by centrifugation
and used for plasmid preparation using an endotoxin-free plasmid
preparation kit following the recommended protocol (Qiagen,
Hercules, CA). Sub-library transformations generating less than 104
original transformants were remade. High diversity (N104) libraries
were used for plasmid DNA isolation. At least 50 μg of plasmid DNA
was prepared from each sub-library. The corresponding pCMViLS and
pCMViUB sub-libraries were mixed together at 1:1 ration and divided
into four 25 -μg aliquots. The aliquots and unused plasmid DNA were
catalogued and stored at −80 °C.
Preparation of gene-gun bullets
Gold spherical microparticles (1–2 μm, RDAU11K-20; Ferro
Electronic Material Systems, South Plainﬁeld, NJ) were washed
twice with water and ethanol and stored frozen in low retention
tubes as 50 mg/ml water slurry. To prepare 100 bullets, 1 ml of gold
slurry was mixed with 100 μg of DNA and total volume adjusted to
2 ml with water. Then 2 ml of cold 2.5 M CaCl2 and 100 μl of 1 M
spermidine were quickly added, and the mix was brieﬂy vortexed for
few seconds and left on ice for 10–15 min. Then gold was spun down
by gentle centrifugation (1 min at 200 rcf), supernatant aspirated, and
pellet resuspended in ∼5 ml of 100% ethanol. After two more washes
with ethanol, the gold pellet was resuspended in 5.5 ml of absolute
ethanol with 0.005% polyvinylpyrrolidone and transferred into Teﬂon
tubing (0.125-inch OD, 0.93-inch ID; BioRad, Hercules, CA ) and left on
an even surface for gold to settle. After gold settled, ethanol was
gently drained from the tubing and gold dried by gently ﬂowing dry
nitrogen gas through the tubing. Individual gene-gun cartridges
loaded with 1 μg DNA on 0.5 mg of gold microparticles were made by
cutting the tubing into 0.5-inch sections. The bullets were packed over
Drierite and used within a week.
Large-scale immunizations for screen
Bullets coated with the CPV pool DNAs described above were used
for biolistic vaccination of 6- to 8-week-old female C57BL/6 mice
(Harlan Sprague–Dawley, Indianapolis, IN). Bullets were shot into
dorsal ear pinna with Helios Gene Gun (BioRad) at a helium pressure
of 400 psi. Each mouse received two shots, one into each ear per
immunization, for a total dose of 2 μg. Boosts were administered at
weeks 4 and 8 post-prime with the same dose and delivery protocol.During immunization, animals were housed ﬁve mice per case (2
cases per immunization group) in a pathogen-free environment at the
University of NewMexico. Mice were given food and water ad libitum,
and all procedures were conducted in accordance with federal
guidelines for animal experimentation.
Viral propagation. CPXV-Brighton Red and VACV Western Re-
serve were grown in Vero E6 cells and puriﬁed as described (Joklik,
1962).
Challenge-protection assays
We have previously developed the murine-CPV model of smallpox
disease in C57BL/6 mice and the i.t. route for pulmonary delivery of
virus (MacNeill et al., 2009). Control experiments were conducted on
naïve and vaccinated C57BL/6 mice. The cowpox and VACV were
clonally puriﬁed and quality controlled to ensure virulence. These
were used as live inocula to intraperitoneally vaccinate mice to
establish a positive control for vaccination (5×102 pfu/ml, 50 μl per
mouse). Challenge material stocks were prepared and lethal dose
titrations were conducted to establish the minimum dose necessary
for lethality. This was designed to maximize the sensitivity of the
screen. To assay protection, animals were challenge with 1 LD100
(5×104 pfu/mouse) by i.t. route at week 14. Mouse survival was
monitored and recorded twice daily for 14 days. Data were analyzed
as described in results.
Production of clonal genetic immunization constructs for the validation
studies
ORFs selected by the protection assay screen were re-synthesized
as described above and individually dU cloned into pCMViLS and
pCMViUB. Randomly selected clones were sequenced to identify those
carrying the intended ORF sequence. Perfect clones were used for
large-scale DNA production and puriﬁcation using endotoxin-free
plasmid preparation kit (Qiagen).
Generation of prokaryotic expression constructs and protein production
For the large-scale protein production, sequence-conﬁrmed ORFs
described above were sub-cloned into one of the commonly used
prokaryotic expression vectors: pGEX52 (Amersham Biosciences,
Piscataway, NJ); pEXP5-NT (Invitrogen, Carlsbad, CA); or pBAD/Thio
(Invitrogen). The constructs were used for transformation of the
appropriate host strains: BL21(λ)DE3 for those cloned into pEXP5-
NT and pGEX52; and LMG194 for those in pBAD/Thio. Cells were
grown and induced according to the recommended protocols. Cells
were harvested 3–4 h after induction by centrifugation and the
resulting cell pellet lysed by resuspension in phosphate-buffered
saline (PBS) containing 1% Triton X-100, 1 mM phenylmethylsul-
fonylﬂuoride (PMSF), and protease inhibitor cocktail (Complete,
Roche, Indianapolis, IN). Cell walls were permeabilized with 10 mg
of lysozyme and subjected to three freeze/thaw cycles between
−80 °C and room temperature. The viscous lysate was cleared in a
1-h incubation at 4 °C with 10 μg/ml of DNase I and 20 mM MgCl2.
The lysate was centrifuged at 27,000×g for 10 min at 4 °C, and
the supernatant containing the soluble material was transferred to
a fresh tube. The insoluble material, remaining in the pellet of the
cleared lysate, was washed four times in PBS containing 1% Triton
X-100 and 0.5 M guanidine followed by three washes with PBS.
Cells were collected between washes by centrifugation at 3000×g
for 5 min at room temperature. After the ﬁnal PBS wash, the
inclusion bodies were resuspended in PBS, ﬂash-frozen in liquid
nitrogen, and stored at −80 °C until ready for use. To solubilize the
inclusion bodies, the pellets were resuspended in PBS containing
8 M urea and 10% glycerol. Insoluble material was removed by
centrifugation at 14,000×g for 5 min at room temperature, and the
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Immunization regimen for immune analyses
For the immune studies, 6- to 8-week-old female C57BL/6 mice
(Harlan Sprague–Dawley, Indianapolis, IN) were housed in a
pathogen-free environment at the Biodesign Institute at Arizona
State University. Mice were given food and water ad libitum, and all
procedures were conducted in accordance with federal guidelines for
animal experimentation.
The ORF clones in pCMViUB and pCMViLS were mixed at a 1:1
ratio, precipitated onto bullets, and delivered biolistically into mice as
described above. Each mouse received 2 μg of DNA at weeks 0, 1, and
5. Mice received a ﬁnal boost of DNA at week 22 (samples CPV 100,
CPV 225, CPV 106, and CPV 204) or a boost of protein at week 23
(remaining samples). Mice immunized with protein were injected
with 25 μg of antigen emulsiﬁed 1:1 with TiterMax adjuvant
(TiterMax, Norcross, GA) delivered in three 50 -μl subcutaneous
injections. Mice were sacriﬁced 11 days later, and both sera and
splenocytes were harvested.
ELISA assays
Antigen-speciﬁc antibody titers were measured in an indirect
ELISA using selected peptides or peptide pools since recombinant
proteins produced in E. coli were insoluble. Immulon 2-HB 96-well
plates (Thermo Fisher Scientiﬁc, Waltham, MA) were coated over-
night at 4 °C with 2 μg /ml of peptide or peptide pool diluted in PBS.
Wells were blocked with 2% (w/v) bovine serum albumin (BSA)
in PBS. Sera, diluted two-fold serially in PBS containing 0.05% (w/v)
BSA and 0.1% polyoxyethylene sorbitol monolaurate (Tween 20)
starting at 1/100, were added to blocked wells and incubated for 1 h
at 37 °C. Bound antibody was detected by sequential 1-h incubations
at 37 °C with horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG/IgM-speciﬁc polyclonal antibody and 2,2′ azino-bis
(3-ethylbenzylthiazoline-6-sulphonic acid, ABTS) substrate (both
from Kirkegaard & Perry Laboratories, KPL, Gaithersburg, MD).
Conversion of the substrate was quantiﬁed at 405 nm using an
ELISA plate reader (Molecular Devices, Sunnyvale, CA). Reactivity of
sera from mice immunized with constructs expressing candidates
CPV 225a, CPV 110a, CPV 100a, a fragment of CPV 097b, CPV 066, and
CPV 030a were evaluated against synthetic peptides derived from
regions of the corresponding proteins in ELISA assays. All sera were
tested in two-fold dilution series. Endpoint titers were determined as
the reciprocal dilution at which the mean absorbance value of the test
serum was at least twice that of the mean absorbance value of the
background (diluent alone). Sequences of speciﬁc peptides selected for
use in ELISAs are as follows: CPV 225a_pep3 B12, DVPYEHINGKCNGT-
DYNSNN; CPV 110a_pep1, DEQIYAFCDANKDDIRCKCI; CPV 110a_pep2,
NKDDIRCKCIHPDKSIVRIG; CPV 110a_pep3, HPDKSIVRIGIDTRLPYYCW;
CPV 110a_pep4, IDTRLPYYCWYEPCKRSDAL; CPV 110a_pep5, YEPCK-
RSDALLPASLKKNIS; CPV 110a_pep6, LPASLKKNISRCNVSDCTIS; CPV
110a_pep7, RCNVSDCTISLGNVSITDSK; CPV 110a_pep8, LGNVSIT-
DSKLDVNNVCDSK; CPV 110a_pep9, LGNVSITDSKLDVNNVCDSK; CPV
110a_pep10, RVATENIAVRYLNQEIRYPI; CPV 110a_pep11, YLNQEIRY-
PIIDIKWLPIGL; CPV 110a_pep12, IDIKWLPIGLLALAILILAF; CPV 110a_
pep13, LALAILILAFF; CPV 100a_pep16 H6, SDRTAEGQQSLINLYNKMQT;
CPV 097b_pep14 F8, SGKEPISDYSAEVERLMELP; CPV 097b_pep16 F10,
VKTDIVNTTYDFLARKGIDT; CPV 066a_pep1, TINEKNLEFDTWKDVIHN-
DE; CPV 030a_pep7 C3, AVRYYDGDIYELAKEINAMS; CPV 030a_pep15
C11, LSHLKVALYRRIQRRYPIDD; CPV 030a_pep16 C12, RIQRRYPIDDD-
VDR. Background reactivity was too high on the remaining peptides
to evaluate sera of mice immunized with CPV 171a and CPV 120f,
by ELISA. For these immune sera, only immunoblot analyses were
conducted.Immunoblot analyses
Antibody responses to the vaccine candidates were evaluated by
immunoblot analysis. CPV 171a and CPV 172 were expressed with an
N-terminal thioredoxin fusion. CPV 165 was generated as two
glutathione-S-transferase (GST)-tagged fragments spanning the full-
length protein. Insoluble inclusion bodies of CPV 030a, CPV 066a, CPV
110a, and CPV 171a were used. Recombinant proteins were solu-
bilized in urea, fractionated in SDS–PAGE, and transferred to
nitrocellulose membranes (BioRad, Hercules, CA). Blots were blocked
with casein in PBS (Pierce, Rockford, IL) and probed with a 1:250
dilution of mouse anti-sera followed by HRP-conjugated, goat anti-
mouse IgG/IgM antibody (KPL). Reactive bands were detected with
3,3′,5,5′-tetramethylbenzidine (TMB) substrate (Pierce).
IFN-γ ELISPOT assays
CD4+ and CD8+ T cell responses to the CPV vaccine candidates
were evaluated by quantifying the number of splenocytes of vacci-
nated mice secreting IFN-γ in response to antigen-speciﬁc stimu-
lation. ImmunoSpot plates (Millipore, Billerica, MA) were coated
with rat anti-mouse IFN-γmonoclonal antibody (BD Pharmingen, San
Diego, CA) and blocked with RPMI-1640 medium containing L-
glutamine and supplemented with 10% (v/v) FBS (Gemini Bio-
Products, West Sacramento, CA) and penicillin/streptomycin solution
(Cambrex, East Rutherford, NJ). Splenocyte suspensions isolated from
vaccinated mice were seeded in triplicate or quadruplicate wells of
ImmunoSpot plates at densities from 2.5×105 cells/well to 1×106
cells/well. Cells were stimulated with full-length protein or peptide
pools consisting of 20-mers overlapping in sequence by 10 amino
acids (Alta Bioscience, Edgbaston, Birmingham, UK). All peptide
sequences are available upon request. Proteins were assayed at 20 μg/
ml while the peptide pools were assayed at 10 μg/ml. Control wells
contained splenocytes incubated with medium alone (no antigen).
After 18–22 h, captured IFN-γwas detected by the sequential addition
of biotin-labeled rat anti-mouse IFN-γ monoclonal antibody (BD
Pharmingen) and horseradish peroxidase-labeled avidin D (Vector
Labs, Burlingame, CA). Spots produced by the conversion of 3-amino-
9-ethylcarbazole substrate (AEC, BD Pharmingen) were quantiﬁed
with an ImmunSpot Analyzer (Cellular Technology Ltd., Cleveland,
OH). Data are presented as the number of antigen-speciﬁc spot-
forming units (SFU) per million splenocytes. SFU counts were
adjusted for background by subtracting the number of spots in wells
containing splenocytes in medium alone.
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